BIO GREEN MED SOLUTION - BGMS 6 PERP (BGMSP) Stock Overview
USA - NASDAQ:BGMSP - US23254L2079
BGMSP Key Statistics, Chart & Performance
The current stock price of BGMSP is 6 USD.
BGMSP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.83 | 389.72B | ||
| AMGN | AMGEN INC | 12.52 | 146.96B | ||
| GILD | GILEAD SCIENCES INC | 14.48 | 139.09B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.77 | 98.90B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.36 | 59.77B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.51B | ||
| ARGX | ARGENX SE - ADR | 76.77 | 43.55B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.71 | 38.76B | ||
| INSM | INSMED INC | N/A | 28.96B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.58B | ||
| NTRA | NATERA INC | N/A | 22.37B | ||
| BIIB | BIOGEN INC | 8.58 | 20.14B |
Related stock screener links
About BGMSP
Company Profile
Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the provision of cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company is headquartered in Berkeley Heights, New Jersey. The firm is focused on developing cancer medicines based on cell cycle, epigenetics and mitosis biology. Its epigenetic/anti-mitotic program is evaluating plogo, a Polo-like kinase 1 (PLK1) inhibitor, in solid tumors and hematological malignancies. PLK1 is a serine/threonine kinase with a central role in cell division, or the mitotic phase of the cell cycle, and is a regulator of the DNA damage checkpoint. The Company’s plogo is a novel, small-molecule, selective and potent PLK1 inhibitor, which has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and efficacy in human tumor xenografts at non-toxic doses. Its translational biology program supports the development of plogo in solid tumor and hematological malignancy indications. PLK1 over-expressing tumors include colorectal, esophageal, gastric, leukemia, lung, lymphoma, ovarian and squamous cell cancers.
Company Info
BIO GREEN MED SOLUTION - BGMS 6 PERP
200 Connell Dr Ste 1500
Berkeley Heights NEW JERSEY US
Employees: 0
Phone: 19085177330
BIO GREEN MED SOLUTION - BGMS 6 PERP / BGMSP FAQ
What is the stock price of BIO GREEN MED SOLUTION - BGMS 6 PERP today?
The current stock price of BGMSP is 6 USD.
What is the ticker symbol for BIO GREEN MED SOLUTION - BGMS 6 PERP stock?
The exchange symbol of BIO GREEN MED SOLUTION - BGMS 6 PERP is BGMSP and it is listed on the Nasdaq exchange.
On which exchange is BGMSP stock listed?
BGMSP stock is listed on the Nasdaq exchange.
What is BIO GREEN MED SOLUTION - BGMS 6 PERP worth?
BIO GREEN MED SOLUTION - BGMS 6 PERP (BGMSP) has a market capitalization of 13.44M USD. This makes BGMSP a Nano Cap stock.
How many employees does BIO GREEN MED SOLUTION - BGMS 6 PERP have?
BIO GREEN MED SOLUTION - BGMS 6 PERP (BGMSP) currently has 0 employees.
Is BIO GREEN MED SOLUTION - BGMS 6 PERP (BGMSP) expected to grow?
The Revenue of BIO GREEN MED SOLUTION - BGMS 6 PERP (BGMSP) is expected to grow by 88.68% in the next year. Check the estimates tab for more information on the BGMSP EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy BIO GREEN MED SOLUTION - BGMS 6 PERP (BGMSP) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BGMSP, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BGMSP, evaluating the profitability, health, valuation and growth aspects
- BIO GREEN MED SOLUTION - BGMS 6 PERP (BGMSP) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BIO GREEN MED SOLUTION - BGMS 6 PERP (BGMSP) Sales and EPS estimates to see what analysts future expectations are.
- BIO GREEN MED SOLUTION - BGMS 6 PERP (BGMSP) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BIO GREEN MED SOLUTION - BGMS 6 PERP (BGMSP) Insider and Institutional Ownership to learn about the owners and their transactions.
- BIO GREEN MED SOLUTION - BGMS 6 PERP (BGMSP) Stock Chart to make your own analysis
- BIO GREEN MED SOLUTION - BGMS 6 PERP (BGMSP) Latest news and press-releases to stay up to date.
Does BIO GREEN MED SOLUTION - BGMS 6 PERP (BGMSP) stock pay dividends?
BIO GREEN MED SOLUTION - BGMS 6 PERP (BGMSP) has a dividend yield of 5%. The yearly dividend amount is currently 0.03. Check the full fundamental report for a detailed analysis of BGMSP dividend history, reliability and sustainability.
When does BIO GREEN MED SOLUTION - BGMS 6 PERP (BGMSP) report earnings?
BIO GREEN MED SOLUTION - BGMS 6 PERP (BGMSP) will report earnings on 2025-11-10.
What is the Price/Earnings (PE) ratio of BIO GREEN MED SOLUTION - BGMS 6 PERP (BGMSP)?
BIO GREEN MED SOLUTION - BGMS 6 PERP (BGMSP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-122.02).
BGMSP Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to BGMSP.
BGMSP Financial Highlights
Over the last trailing twelve months BGMSP reported a non-GAAP Earnings per Share(EPS) of -122.02. The EPS increased by 96.85% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -146.06% | ||
| ROE | -177.03% | ||
| Debt/Equity | 0 |
BGMSP Forecast & Estimates
For the next year, analysts expect an EPS growth of 39.49% and a revenue growth 88.68% for BGMSP